SCHEMBL9910027

SCHEMBL9910027

CNC(=O)c1ccc(C2(c3nc(-c4cnccn4)cs3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 2/20 0.43
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC1 Q13547 1/20 0.40
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
ADORA3 P0DMS8 5/20 0.36
CYP17A1 P05093 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP21A2 P08686 1/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4A O75164 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13494265 0.91 HDAC1 (0.46) GRM1HDAC8HDAC6HDAC1ADORA3
SCHEMBL9910026 0.86 ADORA3 (0.51) GRM1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL197118 0.85 HDAC1 (0.42) GRM1HDAC8HDAC6HDAC1HTT
SCHEMBL9910030 0.84 MAPT (0.49) GRM1HDAC6HDAC1MAPTSMN1; SMN2
SCHEMBL197854 0.83 HDAC1 (0.54) HDAC8HDAC6HDAC1HDAC2
SCHEMBL2699762 0.80 HDAC1 (0.43) GRM1HDAC8HDAC6HDAC1HDAC2
SCHEMBL199795 0.77 HDAC1 (0.50) HDAC8HDAC6HDAC1CYP1A2CYP2C19
SCHEMBL2699763 0.77 HDAC1 (0.53) GRM1HDAC1HDAC2
SCHEMBL1920158 0.77 ADORA3 (0.52) GRM1HDAC6MAPTSMN1; SMN2NPC1
SCHEMBL9910025 0.76 CDK2 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 GRM1 1906/4885HDAC8 8/4885HDAC6 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.